WHO/WHE/IHM/GIM/2017.1

## WHO Advisory Committee on Variola Virus Research

### Report of the Eighteenth Meeting

Geneva, Switzerland

2-3 November 2016



INFECTIOUS HAZARD MANAGEMENT WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting

# WHO Advisory Committee on Variola Virus Research

Report of the Eighteenth Meeting

Geneva, Switzerland

2 and 3 November 2016

#### © World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <u>https://creativecommons.org/licenses/by-nc-sa/3.0/igo</u>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation**. WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting, Geneva, Switzerland: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

**Sales, rights and licensing.** To purchase WHO publications, see <u>http://apps.who.int/bookorders</u>. To submit requests for commercial use and queries on rights and licensing, see <u>http://www.who.int/about/licensing</u>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of the WHO Adivsory Committee on Variola Virus Research and does not necessarily represent the decisions or the policies of WHO.

#### Contents

Exect	utive Summary7	
1. Report of the WHO Secretariat - Dr Peter Salama, Dr Sylvie Briand, Dr A. Khalakdina and Mr A. Costa 9		
2.	Report on research proposals submitted to WHO in 2015-2016 - Professor D. Evans	
3. Kolts	Report on the variola virus collection at the WHO Collaborating Centre Repository in VECTOR, ovo, Novosibirsk Region, Russian Federation – Dr S. Shchelkunov	
4. Ortho Amer	Report on the variola virus collection at the WHO Collaborating Centre for Smallpox and Other poxviruses at the Centers for Disease Control and Prevention, Atlanta, Georgia, United States of rica - Dr I. Damon	
5.	Update variola virus repositories biosafety inspection visits - Dr K. Kojima	
6. updat	Use of live variola virus to determine whether mice are a suitable animal model for human smallpox: e on disease pathogenesis - Dr C. Hutson	
7. diagn	Use of live variola virus to maintain and regenerate non-infectious variola derived materials for ostic development support – Dr I. Damon	
8.	Use of live variola virus to evaluate antiviral agents against smallpox - Dr V. Olson	
9. "thirc	Use of live variola virus to support less-reactogenic vaccine development: continued evaluation of "generation vaccines - Dr V. Olson	
10.	Gene sequencing of variola virus in a Lithuanian mummy – Professor G. Smith	
11.	Update on LC16m8 vaccine - Dr H. Yokote	
12.	Update on smallpox vaccine IMVANEX®/ IMVAMUNE® - Dr N. Samy	
13.	Progress towards approval and deployment of TPOXX®/ Arestyvr® (ST-246) - Dr D. Hruby	
14.	Update on the development of Brincidofovir (CMX001) for smallpox - Dr F. Gray	
15. Boric	FDA perspective on the development and approval of smallpox medical countermeasures - Dr L.	
16.	An interactive modelling approach to assessing the role of antivirals - Dr A. Kosaraju25	
17.	Discussion on criteria for approval of essential public health research	
18.	Recreation of horsepox virus using synthetic biology - Professor D. Evans	
19.	General Discussion	
20.	Closing and next steps	

#### Annexes

ANNEX 1. Research proposals submitted to WHO in 2015-2016	. 37
ANNEX 2. Abstracts of presentations	. 38
ANNEX 3. Agenda of the Eighteenth meeting of the Advisory Committee on Variola Virus Research	. 50
ANNEX 4. List of participants	. 53
ANNEX 5. Terms of Reference of the Advisory Committee on Variola Virus Research	. 56

WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting

#### **Executive Summary**

The Advisory Committee on Variola Virus Research (ACVVR) held its Eighteenth meeting on 2 and 3 November 2016 at WHO Headquarters in Geneva.

#### **ACVVR** functioning

As requested by the 69<sup>th</sup> World Health Assembly in May 2016, the Advisory Committee's Terms of Reference have been refreshed and the membership has been expanded to include new members including those with specific expertise in synthetic biology and public health preparedness.

The Advisory Committee reviewed the implications for its upcoming work in light of the 69<sup>th</sup> World Health Assembly's decision to have a substantive agenda item at the 72<sup>nd</sup> World Health Assembly in May 2019 on the destruction of smallpox virus stocks. The Advisory Committee is expected to address research priorities in the interim period cognizant that the risk of smallpox re-emergence has increased as a result of the advent of synthetic biology technologies.

#### **Reports on the virus collections**

The Advisory Committee received reports on the virus collections held at the two WHO Collaborating Centres that are authorized as repositories of variola virus: the State Research Centre for Virology and Biotechnology (VECTOR), Koltsovo, Novosibirsk Region, Russian Federation, and the US Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America (USA).

#### Update on research

The Advisory Committee was updated on continuing research projects using live variola virus for the development of diagnostic tests, animal models, smallpox vaccines, and antiviral and therapeutic agents. Five research projects were deemed "essential public health research" using live variola virus and therefore approved in 2016 out of eight submitted.

Participants from CDC reported to the Advisory Committee on progress and challenges in the development of humanized mouse models for use in testing variola virus treatments. It was noted that CDC's research to validate a variola virus specific lateral flow assay (a diagnostic tool) was progressing, as were efforts to produce monoclonal antibodies as a possible therapeutic treatment strategy. CDC also described continuing research on the neutralizing capacity of two third generation vaccines, IMVAMUNE and LC16m8. VECTOR did not conduct research for much of 2016 due to scheduled shutdowns for decontamination and maintenance and for licensure and biennial biosafety inspections. However, in 2016 the Russian Federation had approved the use of a Russian-developed PCR multiplex real-time orthopoxvirus test kit for clinical use within the Russian Federation.

Progress was reported by the manufacturer on the development of IMVANEX/ IMVAMUNE. Although the vaccine's phase three clinical trial was still on going, the company planned to initiate new research into the vaccine's potential use as a treatment for monkeypox in high risk populations.

The manufacturer of TPOXX (Arestyr®/ ST-246), one of two antiviral treatments under development, reported that the product was edging closer to licensure. Efficacy and pharmacokinetic studies in animals had been successfully completed and all other required studies were underway for licensure application that was being prepared. Rabbitpox model studies in Brincidofovir (CMX001), a second antiviral being investigated as a treatment for smallpox, had been completed. Studies in the ectromelia model were ongoing.

The Advisory Committee also received a report from the US Food and Drug Administration on progress toward completing the studies required for the approval of various vaccines, diagnostic tests, and therapeutic medications for use with smallpox. No clear dates were provided for licensure.

The Advisory Committee was also presented with the results of orthopoxvirus research using synthetic biology. One study used bioinformatic phylogenetics to analyse the oldest known variola virus found in a Seventeenth century mummy. The other investigation described the synthesis of a horsepox virus using available commercial biotechnology.

#### **Repository biosafety inspections**

The WHO Smallpox Secretariat reported on the status of the biosafety inspection visits for the two smallpox repositories. For the current round, VECTOR's biennial biosafety inspection was completed in 2016, and CDC's was slated for May 2017.

#### **Recommendations and observations**

- The Advisory Committee strongly concurred with the Independent Advisory Group's assessment in its 2015 report on the Public Health Implications of Synthetic Biology Technology Related to Smallpox, namely that "there will always be the potential to recreate variola virus and therefore the risk of smallpox happening again can never be eradicated." The Advisory Committee noted that the advent of synthetic biology means that individuals can now create viruses such as variola, given information that exists in the public domain, and thus the threat that the virus poses to public health will not be eliminated by simply destroying the virus stocks housed in the two global repositories.
- The Advisory Committee strongly recommended that definition and implementation of policy that enhanced preparedness for a possible future smallpox event was highly desirable, especially in the context of the above mentioned capabilities engendered by advances in synthetic biology. They noted, in particular, the importance of point-of-care diagnostic tests as critical in detection of disease and thereby mitigating potential mortality and morbidity. There was consensus on pursuing a research agenda that will ensure point-of-care, generic and sensitive orthopoxvirus diagnostics in the near term. The Advisory Committee acknowledged the important work that both Collaborating Centres have already done to date on developing such diagnostics.
- Advisory Committee Members retained their prior recommendation for use of live variola virus in the development of antiviral drugs. It was observed that two compounds TPOXX® and Brincidofovir were in the final stages of work in their applications for licensure. While

## 预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5\_26409